Amedisys Company Profile (NASDAQ:AMED)

About Amedisys

Amedisys logoAmedisys, Inc. (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company's home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. The Company's hospice segment provides palliative care and comfort to terminally ill patients and their families. The Company's personal care segment provides patients with assistance with the essential activities of daily living. The Company owns and operates approximately 330 Medicare-certified home healthcare centers, over 80 Medicare-certified hospice care centers and approximately nine personal-care care centers in over 30 states within the United States, the District of Columbia and Puerto Rico.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Health Care
  • Sub-Industry: Health Care Services
  • Exchange: NASDAQ
  • Symbol: AMED
  • CUSIP: 02343610
Key Metrics:
  • Previous Close: $48.91
  • 50 Day Moving Average: $46.49
  • 200 Day Moving Average: $44.97
  • 52-Week Range: $34.58 - $55.16
  • Trailing P/E Ratio: 39.33
  • Foreward P/E Ratio: 24.11
  • P/E Growth: 1.48
  • Market Cap: $1.62B
  • Outstanding Shares: 33,569,000
  • Beta: 1.43
  • Net Margins: 2.93%
  • Return on Equity: 11.94%
  • Return on Assets: 7.17%
  • Debt-to-Equity Ratio: 0.20%
  • Current Ratio: 1.06%
  • Quick Ratio: 1.06%
Additional Links:
Companies Related to Amedisys:

Analyst Ratings

Consensus Ratings for Amedisys (NASDAQ:AMED) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $53.71 (11.39% upside)

Analysts' Ratings History for Amedisys (NASDAQ:AMED)
DateFirmActionRatingPrice TargetDetails
3/1/2017Jefferies Group LLCBoost Price Target$57.00View Rating Details
3/1/2017MizuhoBoost Price TargetNeutral -> Neutral$33.00 -> $50.00View Rating Details
1/27/2017Benchmark Co.Initiated CoverageHold$50.00View Rating Details
1/17/2017Craig HallumSet Price TargetBuy$60.00View Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
6/16/2016StephensInitiated CoverageEqual Weight$55.00View Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldView Rating Details
5/6/2016Royal Bank of CanadaBoost Price TargetSector Perform$41.00 -> $48.00View Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$56.00View Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$42.00 -> $45.00View Rating Details
6/9/2015Deutsche Bank AGUpgradeHold -> Buy$28.00 -> $41.00View Rating Details
5/27/2015SunTrust Banks, Inc.UpgradeNeutral -> Buy$31.00 -> $36.00View Rating Details
(Data available from 3/1/2015 forward)


Earnings History for Amedisys (NASDAQ:AMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.44$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.15$0.26$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.04$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114$0.56($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amedisys (NASDAQ:AMED)
Current Year EPS Consensus Estimate: $1.50 EPS
Next Year EPS Consensus Estimate: $2.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20167$0.32$0.35$0.33
Q2 20165$0.38$0.44$0.42
Q3 20165$0.40$0.46$0.43
Q4 20163$0.44$0.53$0.49
Q1 20172$0.42$0.43$0.43
Q2 20172$0.48$0.55$0.52
Q3 20172$0.52$0.56$0.54
Q4 20172$0.58$0.62$0.60
Q1 20181$0.43$0.43$0.43
Q2 20181$0.57$0.57$0.57
Q3 20181$0.62$0.62$0.62
Q4 20181$0.70$0.70$0.70
(Data provided by Zacks Investment Research)


Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.80%
Institutional Ownership Percentage: 94.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amedisys (NASDAQ:AMED)
News IconTrading Sheet: Watching the Levels for Amedisys, Inc. (NASDAQ:AMED) - The Standard (NASDAQ:AMED) - March 1 at 8:13 AM
News IconTrading Roundup: Checking Technicals for Amedisys Inc (AMED) - BVN (NASDAQ:AMED) - March 1 at 8:13 AM logoAmedisys Reports Fourth Quarter and Year End 2016 Financial Results - Yahoo Finance (NASDAQ:AMED) - March 1 at 8:13 AM logoAMEDISYS INC Files SEC form 10-K, Annual Report (NASDAQ:AMED) - March 1 at 8:13 AM logoAmedisys  beats by $0.05, misses on revenue (NASDAQ:AMED) - March 1 at 12:14 AM logoIn China, 12.4 million people brought above poverty line in 2016 - Xinhua (NASDAQ:AMED) - February 28 at 8:36 PM logoMellanox Technologies (MLNX) Trading Near $50.28 Resistance Level (NASDAQ:AMED) - February 28 at 8:36 PM
News IconYear End 2016 Financial Results (NASDAQ:AMED) - February 28 at 8:36 PM logoAMEDISYS, INC. (NASDAQ:AMED) Files An 8-K Results of Operations and Financial Condition (NASDAQ:AMED) - February 28 at 8:36 PM logoAMEDISYS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial S (NASDAQ:AMED) - February 28 at 8:36 PM logoAmedisys tops 4Q profit forecasts (NASDAQ:AMED) - February 28 at 8:36 PM logoAmedisys Reports Fourth Quarter and Year End 2016 Financial Results (NASDAQ:AMED) - February 28 at 7:27 PM logoAmedisys Announces Fourth Quarter Earnings Release and Conference Call Date (NASDAQ:AMED) - February 28 at 9:23 AM logoQ4 2016 Amedisys Inc Earnings Release - After Market Close (NASDAQ:AMED) - February 28 at 9:23 AM
News IconWhat's In the Cards For Amedisys Inc (NASDAQ:AMED)? Analysts Take Their Aim at the Stock - Winfield Review (NASDAQ:AMED) - February 27 at 3:39 PM
News IconAmedisys Inc (NASDAQ:AMED) Analyst Recommendation - NewsDen (NASDAQ:AMED) - February 27 at 7:30 AM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: Pernosky Lawrence R (NASDAQ:AMED) - February 26 at 10:30 AM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: LABORDE RONALD A (NASDAQ:AMED) - February 25 at 8:27 PM logoSentiments And Ratings Alert: Amedisys Inc (NASDAQ:AMED) - Investor Newswire (NASDAQ:AMED) - February 25 at 3:26 PM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: Pernosky Lawrence R - (NASDAQ:AMED) - February 25 at 3:26 PM logoForm 4 AMEDISYS INC For: Feb 22 Filed by: LABORDE RONALD A - (NASDAQ:AMED) - February 25 at 1:43 AM
News IconReading the Numbers on Shares of Amedisys, Inc. (NASDAQ:AMED) - Searcy News (NASDAQ:AMED) - February 24 at 3:41 PM
News IconAre Analysts Optimistic About Where Amedisys Inc (NASDAQ:AMED) is Heading? - Winfield Review (NASDAQ:AMED) - February 22 at 3:30 PM
News IconAnalysts Peer Into Their Crystal Balls For Amedisys Inc (NASDAQ:AMED): Where Is It headed? - Winfield Review (NASDAQ:AMED) - February 21 at 7:17 AM
News IconGlobal Home Healthcare Market is expected to reach USD 517.2 billion by 2025: Radiant Insights (NASDAQ:AMED) - February 16 at 8:35 PM
News IconGlobal Home Healthcare Market is expected to reach USD 517.2 billion by 2025: Radiant Insights (NASDAQ:AMED) - February 16 at 8:35 PM logoDeferred Tax Assets Of Amedisys Inc (NASDAQ:AMED) At $1.953 Millions - (NASDAQ:AMED) - February 16 at 8:23 AM
News IconInside the Numbers for Amedisys, Inc. (NASDAQ:AMED) | Davidson ... - Davidson Register (NASDAQ:AMED) - February 14 at 4:04 PM
News IconChecking the Numbers on Amedisys, Inc. (NASDAQ:AMED) - Midway Monitor (NASDAQ:AMED) - February 14 at 4:04 PM
News IconVolatile Stock Causing a Fracas Mid-Session: Amedisys, Inc. (NASDAQ:AMED) - Aiken Advocate (NASDAQ:AMED) - February 14 at 4:04 PM
News IconLevels in Focus on Shares of Amedisys, Inc. (NASDAQ:AMED) - Davidson Register (NASDAQ:AMED) - February 13 at 3:58 PM
News IconCompany Focus: Zooming in on Shares of Amedisys, Inc. (NASDAQ ... - Baldwin Journal (NASDAQ:AMED) - February 10 at 8:59 PM
News IconMarket Focus: Zooming in on Shares of Amedisys, Inc. (NASDAQ:AMED) - Searcy News (NASDAQ:AMED) - February 9 at 8:33 PM logoAmedisys Inc (NASDAQ:AMED) Accounts Payable Is $33.088 For The Quarter Ended 2016-09-30 - (NASDAQ:AMED) - February 8 at 8:44 PM
News IconBusiness Briefs: Amedisys Closes on New Acquisition - Home Health Care News (NASDAQ:AMED) - February 6 at 8:35 PM logoForm 8-K AMEDISYS INC For: Feb 02 - (NASDAQ:AMED) - February 2 at 3:31 PM logoAmedisys Closes On Acquisition of Home Staff, LLC (NASDAQ:AMED) - February 2 at 3:31 PM
News IconAmedisys Launches Heart Program To Lower Readmissions, Empower Patients - Home Health Care News (NASDAQ:AMED) - February 1 at 8:36 PM logoTygh Capital Management, Inc. Buys Bio-Rad Laboratories ... - Nasdaq (NASDAQ:AMED) - February 1 at 8:36 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Amedisys Inc (NASDAQ:AMED)? - Wall Street Beacon (NASDAQ:AMED) - February 1 at 3:35 PM
News IconAmedisys Unveils Heart Failure Program During American Heart Month - P&T Community (NASDAQ:AMED) - February 1 at 3:35 PM logoAmedisys Unveils Heart Failure Program During American Heart Month (NASDAQ:AMED) - February 1 at 3:35 PM
News IconInvestor Notebook: Focusing in on Shares of Amedisys Inc. (AMED) - Springdale Times (NASDAQ:AMED) - January 31 at 3:40 PM logoTygh Capital Management, Inc. Buys Bio-Rad Laboratories, Amedisys, Cavco Industries, Sells LKQ, Heico, Heska - (NASDAQ:AMED) - January 31 at 3:40 PM logoWaller and Bowman discuss Winx trial #2 (NASDAQ:AMED) - January 31 at 1:43 AM logoForm 8-K AMEDISYS INC For: Jan 30 (NASDAQ:AMED) - January 30 at 8:43 PM logo4:22 pm Amedisys announced that David Mikula will join the Company as Chief Development Officer effective January 30 (NASDAQ:AMED) - January 30 at 8:43 PM logoAmedisys Welcomes David Mikula as Chief Development Officer (NASDAQ:AMED) - January 30 at 4:03 PM logoForm 8-K AMEDISYS INC For: Jan 30 - (NASDAQ:AMED) - January 30 at 3:41 PM
News IconInvestor Hub: Checking on the Numbers for Amedisys, Inc. (NASDAQ:AMED) - The Tribune (NASDAQ:AMED) - January 29 at 8:30 PM


What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

9 brokers have issued 12-month price objectives for Amedisys' stock. Their predictions range from $48.00 to $60.00. On average, they anticipate Amedisys' share price to reach $53.71 in the next year.

When will Amedisys announce their earnings?

Amedisys is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)
  • According to Zacks Investment Research, "Greater part of the last 6 months witnessed Amedisys trading below  the Zacks categorized Medical-Outpnt/Hm Care industry. In fact an unimpressive third-quarter 2016 performance resulted in a slump in the share price return performance of the company. Further, CMS’ recently proposed Home Health rule in 2017 proved grossly unfavorable for Amedisys indicating gloomy scenario ahead. We note that, Amedisys ended the third quarter of 2016 with earnings and revenues in line with the respective Zacks Consensus Estimate. Also, Escalation in operating expenses and margin contractions continue to raise concern. On a positive note, in Home Health, the company witnessed strong organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative for strategically fit merger and acquisition activities. The company’s strong cash balance position further bolsters our confidence in the stock." (2/14/2017)

Who owns Amedisys stock?

Amedisys' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (6.55%), William Blair Investment Management LLC (4.50%), Dimensional Fund Advisors LP (4.13%), State Street Corp (2.06%), Cortina Asset Management LLC (0.98%) and Renaissance Technologies LLC (0.78%). Company insiders that own Amedisys stock include Bruce D Perkins, Donald A Washburn, Jeffrey D Jeter, North Tide Capital, Llc, Peter Ricchiuti and Scott G Ginn.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Systematic Financial Management LP, Dimensional Fund Advisors LP, Renaissance Technologies LLC, AQR Capital Management LLC, New York State Teachers Retirement System and Highland Capital Management LP.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Cortina Asset Management LLC, State Street Corp, GSA Capital Partners LLP, Russell Investments Group Ltd., Denver Investment Advisors LLC, Trexquant Investment LP and Round Hill Asset Management.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amedisys stock cost?

One share of Amedisys stock can currently be purchased for approximately $48.22.

Amedisys (NASDAQ:AMED) Chart for Wednesday, March, 1, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Earnings History Chart

Earnings by Quarter for Amedisys (NASDAQ:AMED)

Dividend History Chart

Dividend Payments by Quarter for Amedisys (NASDAQ:AMED)

Last Updated on 3/1/2017 by Staff